2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

ARS Question 4: Would you use DTG / 3TC as initial therapy?

Yes

A.

No

B.

Not sure

C.

Slide13of65FromMSSaag,MDatNewOrleans, LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICALCONFERENCE, IAS  USA.

GEMINI: Initial ART with DTG/3TC

no drug resistance

Cahn IAS 2019#WEAB0404LB

Slide 14of 51 lide14of65FromMSSaag,MDatNewOrleans, LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICALCONFERENCE, IAS  USA.

Proportion of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 (Snapshot Analysis) by Baseline Plasma HIV-1 RNA

DTG +TDF/FTC (N=717)

DTG +3TC (N=716)

DTG+TDF/FTC

DTG+3TC

531/564 526/576

94

≤100,000 c/mL

91

-2.8

1.9

90

138/153 129/140

>100,000 c/mL

92

89

41/46 45/51

-0.9

>250,000 c/mL

88

83

20/24 16/18

>400,000 c/mL

89

5.6

Baseline viral load strata

12/15 11/13

80

>500,000 c/mL

85

4.6

0

20

40

60

80 100

-30 -20 -10 0 10 20 30 40

Difference inproportion,% (95%CI)

HIV-1 RNA<50 c/mL, %

Eron et al.HIV DARTandEmerging Viruses 2018;Miami, FL. Slides 7.

Cahn et al. Lancet. 2018 [Epub ahead ofprint].

Slide15of65FromMSSaag,MDatNewOrleans, LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICALCONFERENCE, IAS  USA.